{
    "nct_id": "NCT05010772",
    "official_title": "Oral Decitabine-Based Maintenance Therapy in Patients With AML in Remission",
    "inclusion_criteria": "* Patients aged >= 18 years AML who have achieved their FIRST complete response (CR) or complete response with incomplete bone marrow recovery (CRi) and are not immediately candidates for allogeneic stem cell transplant\n* Patients who have received intensive therapy (defined as receiving standard or higher dose cytarabine-based therapy) to achieve remission (CR/CRi) should have received remission induction therapy and at least 1 consolidation cycle. These patients are eligible as long as they are not greater than 2 months from their last consolidation therapy and will be designated as COHORT 1 (intensive induction cohort)\n* Patients who have received lower intensity therapy (defined as receiving low-dose cytarabine [LDAC] or hypomethylating agent [HMA]-based therapy) to achieve remission should have received at least 2 cycles of lower intensity therapy between the time they have achieved CR/CRi and enrollment on this protocol. They will be designated as COHORT 2 (lower intensity induction cohort)\n* For either subgroup (lower or higher intensity), patients who have measurable residual disease may be enrolled on their respective cohort at any time without maximum 'time from consolidation' requirement\n* Eastern Cooperative Oncology Group (ECOG) performance status of < or = 3\n* Serum total bilirubin < or = to 1.5 x the upper limit of normal (ULN)\n* Serum creatinine < or = to 2.5 x ULN\n* Absolute neutrophil count (ANC) > 0.5 x k/uL\n* Platelet count > or = 50 x k/uL\n* For females of childbearing age, they may participate if they:\n\n  * Have a negative serum or urine pregnancy test within 10 to 14 days of enrolling\n  * Agree to either abstinence or 2 effective contraceptive methods (such as barrier methods or hormonal contraception) throughout the treatment period and up to 30 days after discontinuing treatment\n* For male patients with a female partner of childbearing age, they may participate if they agree to either abstinence or 2 effective contraceptive methods throughout the treatment period and up to 30 days after discontinuing treatment\n* Ability to understand and sign informed consent\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Diagnosis of acute promyelocytic leukemia (APL), AML - M3 by French-American-British (FAB) classification based on morphology, immunophenotype, molecular, or cytogenetics studies\n* Diagnosis of AML associated t(15;17) or APL variant. Patients with t(9;22) are also ineligible unless they are unable or unwilling to receive therapy with a tyrosine kinase inhibitor\n* Uncontrolled intercurrent illness including, but not limited to active uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\n* Patients with active CNS (central nervous system) disease\n* Patients with documented hypersensitivity to any components of the study program\n* Females who are pregnant or lactating or intending to become pregnant during the study\n* Patients with history of extramedullary AML, except for CNS involvement that is currently controlled, will not be eligible for enrollment\n* Patient should be removed from current trial if they wish to participate and get treatment on another trial",
    "miscellaneous_criteria": ""
}